内生性乙醇与非酒精性脂肪性肝病研究进展*

doi:10.3969/j.issn.1672-5069.2016.01.032

摘要/Abstract

摘要： 非酒精性脂肪性肝病和酒精性肝病具有相似的病理学特征,使得内生性乙醇在非酒精性脂肪性肝病的进展中可能扮演的重要角色成为肝病学家们关注的新方向。内生性乙醇与肝脏、肠道和肠道细菌以及非酒精性脂肪性肝病的关系密切,给我们提供了解释非酒精性脂肪性肝病病因的新视角。

关键词: 非酒精性脂肪性肝病, 内生性乙醇, 肠道细菌

Abstract: Similar pathologic characteristics between non–alcoholic fatty liver disease and alcoholic liver disease presents a new direction for the hepatologists worldwide that endogenous alcohol may play important role in the development of non–alcoholic fatty liver disease. The closed relationship among endogenous alcohol and liver,intestine,intestinal flora and non–alcoholic fatty liver disease provides a new sight to explain the pathogenesis of non–alcoholic fatty liver diseases.

Key words: Non–alcoholic fatty liver diseases, Endogenous alcohol, Intestinal flora

何崇信, 徐正婕综述, 范建高审校. 内生性乙醇与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2016, 19(1): 109-112.

He Chongxin, Xu Zhengjie, Fan Jiangao. Endogenous alcohol in non–alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 109-112.

参考文献

[1] McManus IR,Contag AO,Olson RE. Characterization of endogenous ethanol in the mammal. Science,1960,131（3393）：102-103.
[2] You M,Fischer M,Deeg MA,et al. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element–binding protein（SREBP）. J Biol Chem,2002,277（32）：29342–29347.
[3] Yu S,Rao S,Reddy JK. Peroxisome proliferator–activated receptors,fatty acid oxidation,steatohepatitis and hepatocarcinogenesis. Curr Mol Med,2003,3（6）：561–572.
[4] 李慧莉,李秀敏. 乙醉诱导肝损伤作用机制概述. 中国药师, 2008,11（9）：1114–1116.
[5] Kwon HJ,Won YS,Park O,et al. Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology,2014,60（1）：146–157.
[6] Ladkin RG,Davies JN. Rupture of the stomach in an African child. Br Med J,1948,1（4552）：644.
[7] Jansson–Nettelbladt E,Meurling S,Petrini B,et al. Endogenous ethanol fermentation in a child with short bowel syndrome. Acta paediatrica,2003,95（4）：502–504.
[8] Spinucci G,Guidetti M,Lanzoni E,et al. Endogenous ethanol production in a patient with chronic intestinal pseudo–obstruction and small intestinal bacterial overgrowth. Eur J Gastroenterol Hepatol,2006,18（7）：799–802.
[9] American Gastroenterological Association Medical Position Statement：Guidelines for the evaluation and management of chronic diarrhea management of chronic diarrhea. Gastroenterology,1999,6（116）：1461–1463.
[10] Hauge T,Persson J,Danielsson D. Mucosal bacterial growth in the upper gastrointestinal tract in alcoholics（heavy drinkers）. Digestion,1997,58（6）：591–595.
[11] Gabbard SL,Lacy BE,Levine GM,et al. The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth. Dig Dis Sci,2014,59（3）：638–644.
[12] Cope K,Risby T,Diehl AM. Increased gastrointestinal ethanol production in obese mice：implications for fatty liver disease pathogenesis. Gastroenterology,2000,119（5）：1340–1347.
[13] Rao RK,Seth A,Sheth P. Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol, 2004,286（6）：G881–G884.
[14] Maier A,Bode C,Fritz P,et al. Effects of chronic alcohol abuse on duodenal mononuclear cells in man. Dig Dis Sci,1999,44（4）：691–696.
[15] Chen P,Torralba M,Tan J,et al. Supplementation of saturated long–chain fatty acids maintains intestinal eubiosis and reduces ethanol–induced liver injury in mice. Gastroenterology,2015,148（1）：203–214.
[16] Qin J,Li R,Raes J,et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature,2010,464（7285）：59–65.
[17] Nicholson JK,Holmes E,Kinross J,et al. Host–gut microbiota metabolic interactions. Science,2012,336（6086）：1262–1267.
[18] Moschen AR,Kaser S,Tilg H. Non–alcoholic steatohepatitis：a microbiota–driven disease. Trends Endocrinol Metab,2013,24（11）：537–545.
[19] Turnbaugh PJ,Ley RE,Mahowald MA,et al. An obesity–associated gut microbiome with increased capacity for energy harvest. Nature,2006,444（7122）：1027–1031.
[20] Ley RE,Turnbaugh PJ,Klein S,et al. Microbial ecology：Human gut microbes associated with obesity. Nature,2006,444（7122）：1022–1023.
[21] Salekzamani Y,Shirmohammadi A,Rahbar M,et al. Association between human body composition and periodontal disease. ISRN Dent,2011,2011（86）：38-47.
[22] Machado MV,Cortez–Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol,2012,11（4）：440–449.
[23] Cani PD,Bibiloni R,Knauf C,et al. Changes in gut microbiota control metabolic endotoxemia–induced inflammation in high–fat diet–induced obesity and diabetes in mice. Diabetes,2008,57（6）：1470–1481.
[24] Membrez M,Blancher F,Jaquet M,et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J,2008,22（7）：2416–2426.
[25] Aron–Wisnewsky J,Gaborit B,Dutour A,et al. Gut microbiota and non–alcoholic fatty liver disease：new insights. Clin Microbiol Infect,2013,19（4）：338–348.
[26] Lirussi F,Mastropasqua E,Orando S,et al. Probiotics for non–alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev,2007,32（1）：D5165.
[27] Ritze Y,Bardos G,Claus A,et al. Lactobacillus rhamnosus GG protects against non–alcoholic fatty liver disease in mice. PLoS One,2014,9（1）：e80169.
[28] Cope K,Risby T,Diehl AM. Increased gastrointestinal ethanol production in obese mice：implications for fatty liver disease pathogenesis. Gastroenterology,2000,119（5）：1340–1347.
[29] Nair S,Cope K,Risby TH,et al. Obesity and female gender increase breath ethanol concentration： potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol, 2001,96（4）：1200–1204.
[30] Volynets V,Kuper MA,Strahl S,et al. Nutrition,intestinal permeability,and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease（NAFLD）. Dig Dis Sci,2012,57（7）：1932–1941.
[31] Zhu L,Baker SS,Gill C,et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis（NASH）patients：a connection between endogenous alcohol and NASH. Hepatology, 2013,57（2）：601–609.
[32] Baker SS,Baker RD,Liu W,et al. Role of alcohol metabolism in non–alcoholic steatohepatitis. PLoS One,2010,5（3）：e9570.
[33] de Medeiros IC,de Lima JG. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease?–A mechanistic hypothesis. Med Hypotheses, 2015,[ahead of print].
[34] Frantz JC,McCallum RE. Growth yields and fermentation balance of Bacteroides fragilis cultured in glucose–enriched medium. J Bacteriol,1979,3（137）：1263–1270.
[35] Amaretti A,Bernardi T,Tamburini E,et al. Kinetics and metabolism of Bifidobacterium adolescentis MB 239 growing on glucose,galactose,lactose, and galactooligosaccharides. Appl Environ Microbol,2007,11（73）：3637–3644.
[36] Weimer PJ,Zeikus JG. Fermentation of cellulose and cellobiose by Clostridium thermocellum in the absence and presence of Methanobacterium thermoautotrophicum. Appl Environ Microbol, 1977,2（33）：289–297.
[37] Engstler AJ,Aumiller T,Degen C,et al. Insulin resistance alters hepatic ethanol metabolism：studies in mice and children with non–alcoholic fatty liver disease. Gut,2015,10（11）：30-38.
[38] Simic M,Ajdukovic N,Veselinovic I,et al. Endogenous ethanol production in patients with diabetes mellitus as a medicolegal problem. Forensic Sci Int,2012,216（1–3）：97–100.

内生性乙醇与非酒精性脂肪性肝病研究进展^*

Endogenous alcohol in non–alcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[5]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[6]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[7]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[10]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[11]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[12]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[13]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[14]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.
[15]	钟燕, 苏淑婷综述, 宓余强审校. 非酒精性脂肪性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(1): 145-148.